^
    Back
    Association details:
    Biomarker:NTRK1 mutation
    Cancer:Merkel Cell Carcinoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncotarget
    Title:

    Predictors of immunotherapy benefit in Merkel cell carcinoma

    Published date:
    11/24/2020
    Excerpt:
    ...patients with ARID2 mutations, NTRK1 mutations, or shorter time to recurrence may be expected to have a higher likelihood of benefit from CPIs.
    DOI:
    10.18632/oncotarget.27823